Shigellosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Shigellosis Market Outlook
Thelansis’s “Shigellosis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Shigellosis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Shigellosis
Overview
Shigellosis
is a bacterial infection caused by members of the genus Shigella, which belong
to the tribe Escherichia in the family Enterobacteriaceae. The infection
affects the digestive system and has two basic clinical presentations: watery
diarrhea associated with vomiting, mild to moderate dehydration, and dysentery
characterized by a small volume of bloody mucoid stools and abdominal pain. In
untreated adults, the average duration of symptoms is seven days, and the
organism is cultivated from stools for 30 days or longer. Shigella species are
classified into four species: S dysenteriae, S. boydii, S flexneri and S
sonnei. The hallmarks of shigellosis are the bacterial invasion of the colonic
epithelium and inflammatory colitis, resulting in the characteristic sign of
bacillary dysentery: scanty, unformed stools tinged with blood and mucus. The
diagnosis of shigellosis is usually confirmed by the cultivation of the
etiologic agent from stools and slide agglutination using commercially
available, absorbed rabbit antisera.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment